Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 17 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 11466018

    TGF-β inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  2. US 11464856

    Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers

    Julius-Maximilians-Universitat Wurzburg · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  3. US 11459340

    Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  4. US 11459308

    Broad spectrum inhibitors of filoviruses

    The Government of the United States, as represented by the Secretary of the Army · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  5. US 11453668

    JAK inhibitors containing a 4-membered heterocyclic amide

    Theravance Biopharma R&D IP, LLC · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  6. US 11453683

    KRas G12D inhibitors

    Mirati Therapeutics, Inc. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  7. US 11452714

    Antibacterial agents including histidine kinase inhibitors

    Regents of the University of Minnesota · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  8. US 11452780

    Mtorc1 inhibitors

    The Regents of the University of California · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  9. US 11439641

    Pyrimidine JAK inhibitors for the treatment of skin diseases

    Theravance Biopharma R&D IP, LLC · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  10. US 11439632

    Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients

    Northwestern University · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  11. US 11439629

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  12. US 11439611

    Administration of serine protease inhibitors to the stomach

    The Regents of the University of California · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  13. US 11432547

    Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  14. US 11433118

    Long-acting VEGF inhibitors for intraocular neovascularization

    The Regents of the University of California · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  15. US 11434233

    Heterocyclic inhibitors of ATR kinase

    The Board of Regents of the University of Texas System · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  16. US 11426393

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted
  17. US 11426420

    Inhibitors of short-chain dehydrogenase activity for treating coronary disorders

    The Board of Regents of the University of Texas System · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted
  18. US 11420936

    Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases

    NIKANG THERAPEUTICS, INC. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  19. US 11414379

    SPAK kinase inhibitors as neuroprotective agents

    United States Government as represented by the Department of Veterans Affairs · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted
  20. US 11407712

    Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α

    Arcus Biosciences, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  21. US 11407723

    Selective histone deacetylase inhibitors for the treatment of human disease

    Shuttle Pharmaceuticals, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  22. US 11401286

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  23. US 11401246

    Triazole glycolate oxidase inhibitors

    Century Therapeutics, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  24. US 11390646

    Structure-based peptide inhibitors of α-synuclein aggregation

    The Regents of the University of California · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted